Several molecular mechanisms, not always dependent on EZH2 methyltransferase activity, have been shown to underlie the role of EZH2 in cancer, including repression of tumor suppressors 43, 44, 45, 46, 47, 48, 49, 50, activation of oncogenic NOTCH signaling [47], stabilization of β-catenin [48], and inhibition of DNA damage repair and consequent induction of secondary mutations [50]. The gene discussed is EZH2; the disease is neoplasm.